Product Information
ZARONTIN 250 MG CAPSULE is a brand product labeled by Pfizer Inc., priced at $1.3086 per EA under NDC 00071023724. Its NADAC has been published 313 times since Nov 28, 2013.
FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Ethosuximide market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
250 mg/1
Manufacturer
Pfizer Inc.NDC
00071023724
Classification
Brand
Dosage Form
CAPSULE
Route
ORAL
Effective Date
1/1/2026
Active Ingredients
ETHOSUXIMIDEApproval Type
New Drug (NDA)
FDA Application
NDA012380FDA Approved
Before 1982
TE Code
AB
On Market Since
9/22/2000
Pharmacological Classes
Price Statistics
The NADAC for ZARONTIN 250 MG CAPSULE has been published 313 times since Nov 28, 2013, and over the history we have for it it has declined 30.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.3086 per EA |
|---|---|
| All-time high | $3.5451 (Jan 16, 2019) |
| All-time low | $1.2742 (Oct 22, 2025) |
| 52-week high | $1.3086 |
| 52-week low | $1.2742 |
| Median price | $2.7046 |
| Average price | $2.5933 |
| Largest weekly change | -64.1% (Oct 22, 2025) |
| Weeks tracked | 313 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 81% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of ZARONTIN 250 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for ZARONTIN 250 MG CAPSULE, manufactured by Pfizer Inc., is $1.3086 per EA (NDC 00071023724), effective Aug 19, 2026.
How has the price of ZARONTIN 250 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for ZARONTIN 250 MG CAPSULE has declined 30.9%. It has been tracked across 313 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for ZARONTIN 250 MG CAPSULE?
Since Nov 28, 2013, the NADAC for ZARONTIN 250 MG CAPSULE has ranged from a low of $1.2742 (Oct 22, 2025) to a high of $3.5451 (Jan 16, 2019), with a median of $2.7046 per EA.
Are there cheaper alternatives to ZARONTIN 250 MG CAPSULE?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ETHOSUXIMIDE 250 MG CAPSULE, is $0.2483 per EA — about 81% below ZARONTIN 250 MG CAPSULE.
Who manufactures ZARONTIN 250 MG CAPSULE?
ZARONTIN 250 MG CAPSULE (NDC 00071023724) is labeled by Pfizer Inc., and CMS classifies it as a brand product.